Bryostatin and Vincristine in B-Cell Malignancies

You may not be if

• Performance status: ECOG 0, 1, or 2
• Life expectancy of at least 12 weeks
• Patients with aggressive NHL will be enrolled after having failed all possible therapy with curative intent
• Patients with CLL must have failed an alkylating agent-containing regimen as well as fludarabine chemotherapy
• Patients with multiple myeloma must have received at least one prior chemotherapy regimen and not be eligible for a dose intensification treatment approach
• At least 4 weeks must have elapsed since prior large-field radiation therapy
• Patients must have been off previous anti-cancer therapy for at least 3 weeks (6 weeks for BCNU and mitomycin C) and recovered from all treatment related toxicity
• Prior vincristine therapy is allowed
• Sexually active men and women must use an accepted and effective method of contraception
• In women of child-bearing age, a pregnancy test may be done at the discretion of the investigator
• Must have given written informed consent
• Patients with brain metastasis, leptomeningeal involvement, primary CNS NHL, and acute leukemia are ineligible
• Patients with HIV infection are ineligible
• WBC \< 3000/ul
• Granulocytes \< 1500/ul
• Platelets \< 50,000/ul
• Hemoglobin =\< 8.5 g/dl
• Bilirubin \> 1.5 mg/dl
• AST and ALT \> 2 times normal
• Creatinine \> 2.0 mg/dl, and/or actual creatinine clearance \< 40 ml/min/1.73 m\^2; all patients are required to have a 24 hr creatinine clearance
• Clinical evidence of bleeding diathesis
• ECOG Performance status 3 or 4
• Patients who are pregnant or lactating; vincristine can cause fetal harm
• Patients with clinically apparent neuropathy are ineligible (\>= grade 2 neuropathy)